Author:
Dengiz Alan N.,Kershaw Paul
Abstract
AbstractAlzheimer's disease is a progressive, neurodegenerative condition characterized by deficits in cognition, inability to perform activities of daily living, and alterations in behavior. Galantamine hydrobromide is the newest acetylcholin esterase inhibitor (AChEI) approved in the United State for the treatment of mild-to-moderate AD. The safety and efficacy of galantamine has been demonstrated in multiple randomized, Phase III trials of > 2,600 patients with mild-to-moderate AD. Studies have found that galantamine improved or maintained performance in all domains of AD (cognition, function, behavior, and caregiver burden in the short term and slowed the decline in performance or maintained baseline performance through 12 months. The dual mechanism of action may make galantamine a reasonable treatment option for both newly diagnosed patients and patients who have not benefitted from or have poorly tolerated current therapy.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health,Clinical Neurology
Reference33 articles.
1. NDTI (Diagnosis codes: 3310, 2900, 2901, 2902, 2903, 2904, 33109, 2912) July 2001.
2. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease for the ENA 713 B352 Study Group;Corey-Bloom;Int J Geriatric Psychopharmacol,1998
3. The Disability Assessment for Dementia Scale: A 12-Month Study of Functional Ability in Mild to Moderate Severity Alzheimer Disease
4. Torfs K , Feldman H . 12-month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease treated with placebo in two randomized studies. Poster presented at: World Alzheimer Congress; July 9–18, 2000; Washington, DC.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献